Climb Bio

China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal with US firm Climb Bio, Inc. (NASDAQ: CLYM). Under the agreement, Climb Bio will take exclusive development, manufacturing, and sales rights to Mabworks’ MIL116 (now CLYM116), an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody (mAb) primarily…